TrialArthritis research & therapy2025

Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials.

Laure Gossec et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.